Publications Repository

Publications Repository

Search 
  •   Home
  • ICR Divisions
  • Search
  • Home
  • ICR Divisions
  • Search
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search

Show Advanced FiltersHide Advanced Filters

Filters

Use filters to refine the search results.

Now showing items 1-10 of 25

  • Sort Options:
  • Relevance
  • Issue date (newest)
  • Issue date (oldest)
  • Results Per Page:
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
Thumbnail

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. 

Alumkal, JJ; Chowdhury, S; Loriot, Y; Sternberg, CN; de Bono, JS; Tombal, B; Carles, J; Flaig, TW; Dorff, TB; Phung, D; Forer, D; Noonberg, SB; Mansbach, H; Beer, TM; Higano, CS (2017-10)
BACKGROUND: The Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed ...
Thumbnail

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt? 

Capelan, M; Roda, D; Geuna, E; Rihawi, K; Bodla, S; Kaye, SB; Bhosle, J; Banerji, U; O'Brien, M; de Bono, JS; Popat, S; Yap, TA (2017-09)
OBJECTIVES: Despite advances in novel drug development for patients with advanced non-small cell lung cancer (NSCLC), there are still only a limited number of approved treatments. We therefore evaluated the clinical outcomes ...
Thumbnail

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. 

Evans, JR; Zhao, SG; Chang, SL; Tomlins, SA; Erho, N; Sboner, A; Schiewer, MJ; Spratt, DE; Kothari, V; Klein, EA; Den, RB; Dicker, AP; Karnes, RJ; Yu, X; Nguyen, PL; Rubin, MA; de Bono, J; Knudsen, KE; Davicioni, E; Feng, FY (2016-04)
A substantial number of patients diagnosed with high-risk prostate cancer are at risk for metastatic progression after primary treatment. Better biomarkers are needed to identify patients at the highest risk to guide therapy ...
Thumbnail

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. 

Geuna, E; Roda, D; Rafii, S; Jimenez, B; Capelan, M; Rihawi, K; Montemurro, F; Yap, TA; Kaye, SB; De Bono, JS; Molife, LR; Banerji, U (2015-12)
PI3K-AKT-mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients.Retrospective ...
Thumbnail

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. 

Ameratunga, M; Chénard-Poirier, M; Moreno Candilejo, I; Pedregal, M; Lui, A; Dolling, D; Aversa, C; Ingles Garces, A; Ang, JE; Banerji, U; Kaye, S; Gan, H; Doger, B; Moreno, V; de Bono, J; Lopez, J (2018-01)
BACKGROUND: Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought ...
Thumbnail

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; Kwak, EL; Macarulla Mercadé, T; Geuna, E; Jose de Miguel-Luken, M; Patel, C; Kuida, K; Sankoh, S; Westin, EH; Zohren, F; Shou, Y; Tabernero, J (2017-09-01)
Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid ...
Thumbnail

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. 

George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)
Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...
Thumbnail

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. 

Papadatos-Pastos, D; Roda, D; De Miguel Luken, MJ; Petruckevitch, A; Jalil, A; Capelan, M; Michalarea, V; Lima, J; Diamantis, N; Bhosle, J; Molife, LR; Banerji, U; de Bono, JS; Popat, S; O'Brien, MER; Yap, TA (2017-04)
BACKGROUND: We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient selection ...
Thumbnail

Quantifying sclerotic bone metastases with 2D ultra short TE MRI: a feasibility study. 

Messiou, C; Collins, DJ; Morgan, VA; Robson, MD; deBono, JS; Bydder, GM; deSouza, NM (2010-01)
INTRODUCTION: Ultra Short TE MRI allows signal to be detected from tissues with a very short T2.The aims of this study were to optimize a 2D UTE MRI sequence for imaging and quantification of sclerotic bone metastases, ...
Thumbnail

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. 

Massard, C; Mateo, J; Loriot, Y; Pezaro, C; Albiges, L; Mehra, N; Varga, A; Bianchini, D; Ryan, CJ; Petrylak, DP; Attard, G; Shen, L; Fizazi, K; de Bono, J (2017-01-01)
Background: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the ...
  • «
  • 1
  • 2
  • 3
  • »

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis communityIssue dateAuthorsTitlesSubjects

Discover

Author
De Bono, Johann (25)
Marsden, (15)Mateo Valderrama, Joaquin (7)Banerji, Udai (6)Turner, Lydia (5)... View MoreSubject
Aged (25)
Humans (25)Male (23)Middle Aged (23)Treatment Outcome (13)... View MoreDate Issued2018 (4)2017 (15)2016 (2)2015 (2)2011 (1)2010 (1)

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.